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for the product A and 40% for the product B and were asked for their 
willingness to pay for product A. 
Results: At this time, 31 patients had been enrolled: men: 20 (64,5%), 
age: 64,5 ± 11,7 years, hairless: 4 (13%). In analogical visual scale, 
the impact of alopecia were assessed at 4,7 ± 3,5, median: 5. The mean 
amount patients were willing to pay by 3-week chemotherapy cycle is 
83,3 ± 141,7 euros (median 12,5 euros); 12 (38,7%) of the patients are 
not ready to pay for the product A. 
Discussion and Conclusion: complete results and analysis in rela-
tion with the willingness to pay stratiﬁed by sex, age, employment and 
income will be presented at the meeting. 
P1-245 Supportive Care/QOL Posters, Mon, Sept 3 
Economic impact of second- and third-line erlotinib treatment of 
non small-cell lung cancer: a French observational study
Chouaid, Christos1 Vergnenegre, Alain2 Moser, Aurelie3 Coudray-
Omnes, Carole3 
1 Hôpital Saint Antoine, APHP, Université Pierre et Marie Curie, Paris, 
France 2 CHU Limoges, Limoges, France 3 Roche Pharma France, 
Neuilly, France 
Background: There are few data on the economic consequences of 
targeted cancer therapies. 
Objective: This study examined care consumption and management 
costs among patients who received second- or third-line oral erlotinib 
therapy for non small-cell lung cancer (NSCLC). 
Methods: The study involved two observational cohorts of NSCLC 
second- or third-line treated patients. In the ﬁrst, created in 2005 (be-
fore erlotinib became available), the patients received IV chemotherapy 
alone (IV cohort, 233 patients), while the patients in the second cohort, 
created in 2006, received oral erlotinib (oral cohort, 166 patients). Only 
direct costs were taken into account (drug acquisition and administra-
tion, hospitalization, consultation, costs of managing common toxici-
ties). The analysis adopted the payer’s perspective. 
Results: Treatment lasted a similar length in the IV and oral cohorts 
during second-line treatment (94.5 ± 67.5 and 105 ± 79.4 days, p = 
0.07) but was signiﬁcantly longer in the oral cohort during third-line 
therapy line (76.6 ± 96.5 versus and 114.4 ± 74.5 days, p < 0.008). 
There were more women in the oral cohort (41% versus 26.2%, 
p=0.023) and a higher rate of adenocarcinoma (60.8% versus 47.2%, 
p = 0.0043). There was no difference in smoking status or the disease 
stage at diagnosis. Likewise, the rate of conventional hospitalization 
was not different between the two cohorts. In contrast, during 100 days 
of management, the patients in the oral cohort tended to spend less time 
in hospital during second-line treatment (3 ± 6.6 vs 7.7 ± 18.3 days, p = 
0,057), and the difference was statistically signiﬁcant during third-line 
treatment (4.8 ± 11.7 vs 8.7 ± 14 days, p<0.05). Regardless of the line 
of treatment, the oral cohort made signiﬁcantly fewer stays in daycare 
clinics (p<0.001), and received signiﬁcantly less antiemetic treatment 
(p<0.0001), erythropoietin (p<0.005) and G-CSF (p< 0001). In con-
trast, these patients required more treatment for skin rash (p<0.001). 
Monthly management costs per patient in the IV and oral cohorts were 
respectively 3126 and 2750 euros during second-line treatment and 
3026 and 2823 euros during third-line treatment (no signiﬁcant differ-
ence). A sensitivity analysis showed that the results in the IV cohort 
were dependent on the cost of chemotherapy. 
Discussion: One limit of this study is that transport costs were not 
taken into account. Conclusion: In oral cohort, the cost of Erlotinib 
is compensated by the reduction of daycare hospitalization costs and 
the limited cost of medication to treat adverse events compared to IV 
chemotherapy such as erythropoietin or G-CSF. 
Conclusion: These results must be validated by prospective observa-
tional studies focusing on quality of life and the time spent in hospital. 
This study was supported by Roche Pharma France
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Introduction: A prospective cohort study was undertaken to develop 
risk models for neutropenic complications (NC) consisting of severe or 
febrile neutropenia (FN) among cancer patients receiving chemothera-
py. Models are presented of the risk of such events among lung cancer 
patients initiating a new chemotherapy regimen. 
Methods: Of 907 lung cancer patients, data on 1 or more cycles of che-
motherapy were available on 863 lung cancer patients (665 non small 
cell lung cancer [NSCLC] and 198 small cell lung cancer [SCLC]) 
initiating a new chemotherapy regimen at 115 randomly selected 
U.S. oncology practice sites. Univariate and multivariate proportional 
hazards regression analyses were undertaken to assess the time from 
treatment initiation to the initial NC up to 4 cycles of chemotherapy. In 
the absence of events, patients were censored at the last time seen. 
Results: Of the 863 patients with data on at least 1 cycle of chemo-
therapy, NC (or FN) was experienced over a median of 3 cycles in 15% 
(5%) with NSCLC and over a median of 4 cycles in 40% (18%) with 
SCLC. Four evaluable cycles of treatment were completed in 45% and 
58% of patients with NSCLC and SCLC, respectively. Independent 
clinical risk factors for NC in patients with NSCLC include: leukopenia 
(hazard ratio [HR]=2.1); hyperglycemia (HR=1.8); elevated bilirubin 
(HR=2.6) and alkaline phosphatase (HR=1.7); recent surgery (HR=1.8) 
or chemotherapy (HR=2.9); regimens incoporating cisplatin or carbopl-
atin (HR=4.9), docetaxel (HR=2.2), gemcitabine (HR=2.8), or vinorel-
bine (HR=5.1); planned relative dose intensity >85% (HR=1.8) while 
prophylactic myeloid growth factor was associated with a signiﬁcant 
decrease in risk (HR=0.40). Alternatively, signiﬁcant independent risk 
factors for NC among patients with SCLC include: elevated bilirubin 
(HR=3.9); concurrent immunosuppressives (HR=2.0); regimen based 
on topoisomerase inhibitors (HR=5.1) and age >65 years (HR=1.9) 
and thrombocytopenia (HR=3.4) while reduced risk was observed with 
growth factor prophylaxis (HR=0.41). Model ﬁt for both models was 
excellent by a likelihood ratio test (P<.0001). 
Conclusions: Multivariate analysis for NC identiﬁes overlapping as 
well as distinct risk factors for patients with NSCLC and SCLC receiv-
